Abstract: The present invention provides methods to personalise dietary fiber for an individual based on their CAZyme profile and recommendations for dietary fiber products and compositions as well as systems to facilitate quick and easy use.

Abstract: The invention concerns Lactobacillus reuteri for use in the prevention or treatment of microbiota dysbiosis, in particular, decreased levels of Actinobacteria and increased levels of Proteobacteria, in young mammals and in the prevention or treatment of disorders associated therewith. The microbiota dysbiosis may have been cause by numerous factors including being born by caesarean section, exposure to antibiotics in utero or after birth, or, parenteral feeding, hospitalizing, psychological stress or by gastrointestinal dysfunctions.

Abstract: The invention concerns Lactobacillus reuteri for use in the prevention or treatment of microbiota dysbiosis, in particular, decreased levels of Actinobacteria and increased levels of Proteobacteria, in young mammals and in the prevention or treatment of disorders associated therewith. The microbiota dysbiosis may have been cause by numerous factors including being born by caesarean section, exposure to antibiotics in utero or after birth, or, parenteral feeding, hospitalizing, psychological stress or by gastrointestinal dysfunctions.

Abstract: The invention proposes a nutritional composition comprising selected oligosaccharides that reduces the abundance of Streptococcus bacteria in the gut of infants or young mammals. The infants are preferably infants in needs presenting a relatively high count of Streptococcus. Ultimately the reduction of streptococcus and the related microbiota balance affects and lowers the risk of adiposity or obesity later in life.

Abstract: The invention concerns Lactobacillus reuteri for use in the prevention or treatment of microbiota dysbiosis, in particular, decreased levels of Actinobacteria and increased levels of Proteobacteria, in young mammals and in the prevention or treatment of disorders associated therewith. The microbiota dysbiosis may have been cause by numerous factors including being born by caesarean section, exposure to antibiotics in utero or after birth, or, parenteral feeding, hospitalizing, psychological stress or by gastrointestinal dysfunctions.

Abstract: The present invention relates to nutritional compositions for infants or young children and their health effects, that comprise at least one fucosylated oligosaccharide and at least one N-acetylated oligosaccharide. These nutritional compositions are for use to prevent and/or treat infection in an infant or young child, by promoting and/or reducing specific microbiota communities in an infant or young child.

Abstract: The present invention relates to nutritional compositions for infants or young children and their health effects, that comprise at least one fucosylated oligosaccharide and at least one N-acetylated oligosaccharide. These nutritional compositions are for use to prevent and/or treat infection in an infant or young child, by promoting and/or reducing specific microbiota communities in an infant or young child.

Abstract: The invention relates to a nutritional composition comprising at least one N-acetylated oligosaccharide, and at least one galacto-oligosaccharide, and at least one sialylated oligosaccharide. The composition optionally comprises a Bifidobacterium animalis spp. lactis probiotic, preferably CNCM-I-3446 probiotic. The composition treat ro reduces the risk, the severity and/or the occurrence of non-rotavirus associated diarrhoea. The composition also promotes a healthy intestinal flora and has beneficial long and short terms effects. The composition is in particular intended for infants between 0 and 12 months of age fed predominantly with infant formula.

Abstract: The present invention relates to a nutritional composition comprising at least one fucosylated oligosaccharide and at least one N-acetylated oligosaccharide for use in preventing and/or treating non-rotavirus diarrhea in infants or young children by acting on the dysbiosis of the microbiota preceding and/or following the non-rotavirus diarrhea. The composition can be an infant formula and is in particular intended for infants between 0 and 12 months of age fed predominantly with infant formula. It promotes a healthy intestinal flora and has beneficial short and long terms effects.

Abstract: The invention relates to a nutrition composition with oligofructose and optionally high sn-2 palmitate triglycerides for inducing gut microbiota patterns in the guts of infants or young children that are similar in composition and diversity to the microbiota of breast fed infants. The infants can be 0-12 months or 0 to 36 months of age and the composition can be an infant formula. The composition promotes a healthy intestinal microbiota and can have long term effects.

Abstract: The invention concerns Lactobacillus reuteri for use in the prevention or treatment of microbiota dysbiosis, in particular, decreased levels of Actinobacteria and increased levels of Proteobacteria, in young mammals and in the prevention or treatment of disorders associated therewith. The microbiota dysbiosis may have been cause by numerous factors including being born by caesarean section, exposure to antibiotics in utero or after birth, or, parenteral feeding, hospitalizing, psychological stress or by gastrointestinal dysfunctions.

Abstract: The invention relates to a nutrition composition with promoting or inducing a gut microbiota that is closer to infants fed exclusively with human breast milk, in comparison to infant fed with conventional nutritional composition. The composition is in particular intended for infants between 0 and 12 months of age fed predominantly with infant formula. The infants can be fed during 2, 4, or 6 months and the composition can be an infant formula. The composition promotes a healthy intestinal flora and has beneficial long and short terms effects.

Abstract: The present invention relates to a nutritional composition comprising at least one fucosylated oligosaccharide and at least one N-acetylated oligosaccharide for promoting or inducing a global gut microbiota that is closer to the one of infants fed exclusively with human breast milk, in comparison to infants fed with a conventional nutritional composition. The composition can be an infant formula and is in particular intended for infants between 0 and 12 months of age fed predominantly with infant formula. It promotes a healthy intestinal flora and has beneficial short and long terms effects.

Abstract: The present invention relates to means and methods for modulating the gut microbiota composition of a subject, preferably a human. In particular, the present invention provides an agent capable of reducing the proportion of Lachnospiraceae in the gut microbiota composition of a subject which agent is useful for promoting weight loss or preventing weight gain in a subject, preferably an obese or overweight subject. Lactobacillus rhamnosus CGMCC 1.3724 is particularly preferred as the agent provided by and used in the present invention.

Abstract: The invention relates to a nutrition composition with oligofructose and optionally high sn-2 palmitate for down regulating, decreasing or inhibiting the growth of pathogenic bacterial populations in the guts of infants or young children. The infants can be 0-12 months of age and the composition can be an infant formula. Higher dosage of oligofructose intensifies the effect. The composition promotes a healthy intestinal microbiota.

Abstract: The invention proposes a nutritional composition comprising selected oligosaccharides that reduces the abundance of Streptococcus bacteria in the gut of infants or young mammals. The infants are preferably infants in needs presenting a relatively high count of Streptococcus. Ultimately the reduction of streptococcus and the related microbiota balance affects and lowers the risk of adiposity or obesity later in life.

Abstract: The present invention relates to means and methods for modulating the gut microbiota composition of a subject, preferably a human. In particular, the present invention provides an agent capable of reducing the proportion of Lachnospiraceae in the gut microbiota composition of a subject which agent is useful for promoting weight loss or preventing weight gain in a subject, preferably an obese or overweight subject. Lactobacillus rhamnosus CGMCC 1.3724 is particularly preferred as the agent provided by and used in the present invention.

Abstract: The present invention relates in general to the field of Bifidobacteria. In particular, the present invention relates to the field of Bifidobacteria with a modulated stress resistance. One embodiment of the present invention is a Bifidobacterium with a constitutively modulated DnaK, GrpE and/or CIpB expression.

Abstract: The present invention relates in general to the field of Bifidobacteria. In particular, the present invention relates to the field of Bifidobacteria with a modulated stress resistance. One embodiment of the present invention is a Bifidobacterium with a constitutively modulated DnaK, GrpE and/or CIpB expression.

Abstract: The present invention relates in general to the field of Bifidobacteria. In particular, the present invention relates to the field of Bifidobacteria with a modulated stress resistance. One embodiment of the present invention is a Bifidobacterium with a constitutively modulated DnaK, GrpE and/or CIpB expression.